anticancer agent

Anticancer Agent 110 exhibits potent in vitro anti-leukemia activity, demonstrating high cytotoxicity against K-562 lineage chronic myelogenous leukemia cells at nanomolar concentrations. It induces DNA damage and subsequently triggers apoptosis [1].

(S)-5-chloro-N-(1-((4-chlorophenyl)amino)-1-oxo-3-phenylpropan-2-yl)-2-hydroxybenzamide has antifungal and tuberculostatic activities.

Anticancer agent 3 (Compound 4) is an anticancer agent.

Anticancer agent 129 (Compound 3a) is a quinoline derivative predicted to have anti-cancer activity [1].

Anticancer agent 174 (BA-3) functions as a potent inhibitor of cancer cell proliferation and induces apoptosis via the mitochondrial pathway in melanoma mouse xenograft models [1].

Anticancer agent 136 (compound 22), a C17-triazole analogue of Geldanamycin (GDM), exhibits an IC50 value of 3.38 μM against human dermal fibroblasts (HDF) and binds to Heat shock protein 90 (Hsp90) with a dissociation constant (Kd) of 3.86 μM, demonstrating its apoptosis-inducing capabilities [1].

Anticancer Agent 108 (Compound 3.10) serves as a potent P-gp inhibitor exhibiting considerable antitumor properties while maintaining reduced toxicity to both normal and pseudonormal cells; it also demonstrated no acute toxic effects on C57BL/6 mice [1].

Anticancer Agent 153 (Compound 3) promotes apoptosis through the generation of Reactive Oxygen Species (ROS) and elevates the loss of Mitochondrial Membrane Potential (MMP), effectively inhibiting cancer cell proliferation [1].

Anticancer Agent 146 (Compound 1.19) acts as a necroptosis inducer and demonstrates anti-tumor efficacy in the MDA-MB-231 mouse xenograft model [1].

Compound 103 (Compound 2k) serves as a potent anticancer agent [1].

Anticancer agent 112[1], serves as a potent agent for cancer research.

Anticancer agent 32 (compound 2g) is an anticancer compound that affects the cell cycle and induces apoptosis, making it valuable for cancer research.

Anticancer agent 74 exhibits moderate anticancer activity with lower selectivity and cytotoxicity compared to doxorubicin towards normal cells [1].

Anticancer agent 49 (compound 69) is a broad-spectrum anticancer agent with anti-proliferative activity. Anticancer agent 48 inhibits microtubule protein aggregation and has in vivo antitumour activity, with potential for studies on solid tumours and haematological tumours.

Anticancer agent 66, a ciprofloxacin analog, functions as an anti-cancer agent by inducing apoptosis and elevating the sub-G1 cell population in MCF-7 cells.

Anticancer agent 59, an inhibitor active against various cancer cell lines, particularly demonstrates efficacy in A549 cells with an IC 50 value of 0.2 μM. It prompts apoptosis, elevates Ca2+ and ROS levels within cancer cells, and markedly reduces mitochondrial membrane potential. Additionally, it effectively curtails tumor growth in the A549 mouse xenograft model.

Anticancer agent 70 (Compound 21) is a potent anticancer compound that demonstrates remarkable cytotoxicity against multiple human cancer cell lines. It induces G0/G1-cell cycle arrest and concurrently elevates the levels of p53 and p21 proteins. Furthermore, Anticancer agent 70 induces ATP depletion and disruption of the mitochondrial membrane potential [1].

Anticancer Agent 102, a tetracaine derivative, exhibits anti-cancer activity by inducing apoptosis [1].

Anticancer agent 81 (Compound 37b3) induces tumor cell cycle arrest and apoptosis, and serves as a payload for conjugation with Trastuzumab, forming the antibody-drug conjugate (ADC) T-PBA, which retains Trastuzumab's targeting and internalization properties [1].

Anticancer agent 29 (Compd E Z-6f) exhibits potent anticancer activity with IC50 values of 0.054 μM, 0.127 μM, 0.129 μM, and 0.396 μM for CDK2, CDK1, CDK4, and CDK6, respectively [1].

Anticancer agent 38 (compound 19) is an aryl-urea compound, and is a potent anticancer agent. Anticancer agent 38 inhibits A431 cell growth with an IC 50 of 5.2 μg/mL [1].

Anticancer agent 54 is an effective anticancer agent whose anticancer activity depends on DNA embedding and ROS generation. Anticancer agent 54 has an anti-proliferative effect by blocking the cell cycle in G0/G1 phase and inducing apoptosis.

Anticancer agent 57 (compound 14) demonstrates potent inhibition of MDA-MB-231, MDA-MB-468, and MCF-7 cell lines, with IC50 values ranging from 6.43 to 8.00 μM. Additionally, this agent induces cell cycle arrest and promotes apoptosis. In vivo studies using nude mice xenografted with MADMB-231 cells have shown that Anticancer agent 57 effectively inhibits tumor growth. Consequently, Anticancer agent 57 can serve as a valuable tool for researching triple negative breast cancer (TNBC) [1].

Anticancer agent 34 (compound 9) is a sulfonylurea derivative and a potent anti-microbial and anti-cancer agent. anticancer agent 34 showed inhibition of microbial growth of Mycobacterium, Escherichia coli and Candida albicans (MIC: 0.039-0.156 mg/ml). Anticancer agent 34 inhibited the growth of A549 cells (IC50: 8.4 μg/ml), PC3 cells (IC50: 7.8 μg/ml).

Anticancer agent 79 (compound 3d) is an anticancer compound with good anti-breast cancer activity, exhibiting cytotoxic activity in T47-D cells (IC50= 13.64 ± 0.26 μM).

Anticancer agent 40 (compound 3e) is a potent anticancer agent with effects on SKBR-3 cells (IC50: 0.94 nM), SKOV-3 cells (IC50: 0.98 nM), PC-3 cells (IC50: 0.96 nM), U-87 cells (IC50: 0.95 nM), and HDF cells (IC50: 2.13 nM).

Compound 3a, an anticancer agent and ketone derivative, exhibits potent activity against the A549 cancer cell line, demonstrating an inhibitory concentration (IC50) of 6.62 μM [1].

Anticancer agent 160 (Compound 6), a natural product extracted from Parthenium hysterophorus, exhibits cytotoxicity against HCT-116 cells with an IC50 of 5.0 μM [1].

Compound 6i, an anticancer agent, exhibits promising activity against breast adenocarcinoma [1].

Antioxidant anticancer agent 1 (compound 5) is a Schiff base derivative of pyrimidine and pyrimidine hydroxy-1-naphthaldehyde, exhibiting antibacterial, antioxidant, antifungal, and anticancer properties [1].

Anticancer agent 109 (compound 6-15) acts as an inhibitor targeting the Gas6-Axl axis, demonstrating significant anti-cancer properties. This compound suppresses the expression of Gas6, Axl, p-PI3K, and p-AKT in cancer cells, thereby inducing G1 phase arrest and promoting apoptosis of cancer cells. Additionally, Anticancer agent 109 effectively inhibits tumor growth in nude mouse tumor-bearing models [1].

Anticancer agent 120 (compound 21), an N-acylated derivative of ciprofloxacin, exhibits antibacterial activity and promotes cancer cell apoptosis by inducing ROS [1].

Anticancer agent 183 (compound 4h) exhibits potent inhibition of matrix metalloproteinase-9 (MMP-9), reducing its viability by more than 75% at a concentration of 100 μg mL. Additionally, it demonstrates significant anticancer activity, with an IC50 value of <0.14 μM against the A549 cell line and induces apoptotic [1] processes.

Compound D43 (Anticancer agent 188) inhibits DNA synthesis in TNBC cells, causing cell cycle arrest at the G2 M phase. It exhibits anticancer properties by inducing ROS-mediated apoptosis and DNA damage [1].

Anticancer agent 30 (compound 6f-Z) is a potent 3-arylidene-2-oxindole derivative that acts as a selective CDK2 inhibitor, showing significant anticancer activity and potential as a cancer treatment [1].

Anticancer Agent 118, an N‑acylated ciprofloxacin derivative, exhibits antibacterial efficacy against Gram-positive strains and antiproliferative effects on prostate PC3 cells, making it a potential candidate for antitumor research [1].

Anticancer agent 137 (8q), a potent PI3k inhibitor, exhibits broad-spectrum anticancer activity by inducing G2/M cell cycle arrest and apoptosis. It increases levels of cleaved PARP, and caspases 3 and 7, making it useful in cancer research [1].

Anticancer agent 50 (compound 6), a potent modulator of the ABCB1 efflux pump, exhibits cytotoxic and anti-proliferative activity by reducing cyclin D1 expression and inducing p53 expression. It shows significant potential for research in T lymphoma.

Compound 6h (Anticancer Agent 139) exhibits potent anticancer activity, engaging in a π-cationic interaction with Lys352 of Tubulin and demonstrating high efficacy against SNB-19, OVCAR-8, and NCI-H460 with PGIs of 86.61, 85.26, and 75.99, respectively. Moreover, it shows moderate activity against a range of other cancer cell lines — HOP-62, SNB-75, ACHN, NCI/ADR-RES, 786-O, A549/ATCC, HCT-116, and MDA-MB-231 — with PGIs between 51.88 and 67.55 [1].

Anticancer agent 126 (compound 12), a WDR5 inhibitor, exhibits anticancer properties by disrupting the WDR5-MYC interaction in cells, subsequently reducing MYC target gene expression [1].

Anticancer Agent 143 (Compound 369), a potent dual inhibitor targeting PTPN2 and PTP1B, exhibits IC50 values below 2.5 nM. It is employed in cancer research [1].

Compound 107 (Compd 11jc) exhibits potent antitumor activity and serves as an effective anticancer agent in the investigation of pulmonary metastatic melanoma [1].

Anticancer agent 80 (Compound 3c) exhibits a significant dark toxic effect on T47-D cells, with an IC50 of 10.14 μM.

Anticancer agent 92 is an anticancer agent that is nontoxic against noncancerous cells .

Anticancer agent 61 is an orally active anticancer agent. anticancer agent 61 was able to inhibit the proliferation of HepG2, Bel-7402 and MCF-7 cancer cells with IC50 values of 1.12, 1.97 and 1.08 μM respectively. anticancer agent 61 inhibited tumour Anticancer agent 61 was able to inhibit tumour growth.

Compound 12, also known as Anticancer agent 68, functions as an anti-cancer agent by arresting cells at the G2/M phase and inducing programmed cell death. Moreover, it promotes tumor suppression by activating p53 and PTEN [1].

Anticancer agent 65 showed good results in tumour cell lines, especially A549 cells (IC50: 1.07 μM). anticancer agent 65 blocked the cell cycle of A549 cells in S phase, induced apoptosis, increased the expression of p53 and p21, and contributed to ROS generation and MMP collapse.

Anticancer agent 51 (compound 3d) is a potent anticancer compound (Ki: 731.62 nM) with activity against prostate cancer, indicating its potential for prostate cancer research.